Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ter, Genzyme

generated approximately $373 million in cash from net income prior to

one-time events and proceeds from the issuance of common stock. The

company invested approximately $122 million in capital projects to

expand manufacturing capacity to meet current and anticipated product

demand. The company also made a $150 million investment in Isis

Pharmaceuticals associated with the license of mipomersen, a highly

promising product candidate in late-stage development.

-- Genzyme is also using a portion of its operating cash flow to

repurchase shares under a three-year program to reduce the dilutive

effect of equity compensation. The company repurchased 1 million

shares in the first quarter and has repurchased approximately 4.5

million shares since this program began one year ago.

"We had a very strong first quarter to start the year," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We continue to focus on our commitment to deliver 20 percent non-GAAP earnings growth through 2011, while building the company to ensure that we sustain our growth over the longer term."

Financial Guidance

-- Genzyme expects 2008 non-GAAP earnings of approximately $3.90 per

diluted share, compared with prior guidance of $4.00 per diluted share.

This previously announced adjustment reflects the delay in FDA approval

of 2000L production capacity for Myozyme.

-- GAAP earnings in 2008 are expected to be approximately $2.65 per

diluted share, compared with prior guidance of approximately $2.75 per

diluted share. GAAP figures include anticipated amortization and

stock-compensation expenses and the effect of contingent convertible

debt.

-- Genzyme reaffirmed its commitment to 20 percent growth in compound non-

GAAP earnings per share through 2011. No
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the industry ... and internationally, intends to open a full service medical ... Mexico , bringing advanced scientific tools and methodology ... Steep Hill is currently the only laboratory licensed ... potency and contaminant testing in order to meet the ...
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... ARLINGTON, Va., July 13 The Generic Pharmaceutical Association ... Kathleen Jaeger on the Senate HELP Committee,s vote on biogenerics legislation. ... disappointed that the Committee action could result in patients having little ... in the House to ensure that a true balance is achieved ...
... 13, 2009) Whitehead Institute scientists have developed a ... target diseases that until now have stymied drug developers, ... yeast to synthesize and screen the molecules, cutting target ... weeks. The current drug discovery process ...
... ERT (Nasdaq: ERES ), a leading provider of ... medical device, and related industries, announced today that it will release ... 2009 after the market closes. After the release, the Company will ... , For the conference call, interested ...
Cached Biology Technology:GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4ERT to Announce 2009 Second Quarter Results on July 30, 2009 2
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... AURORA, Colo. (Dec. 9, 2013) A new study shows ... concussions than those closer to sea-level, a phenomenon attributed to ... tightly in the skull. "This is the first time ... Comstock, PhD, associate professor of epidemiology at the Colorado School ...
... Liver (EASL) today publishes their revised Clinical Practice Guidelines ... (HCV) (1). The EASL guidelines, which supersede the ... physicians and other healthcare providers optimise their management of ... estimated that approximately 160 million individuals, i.e. 2.35% of ...
... of tumours in over one per cent of all cancer ... has been broadly linked to cancer development. The team ... activated that increases tumour growth. Drugs that inhibit the biological ... in development thus highlighting a potential new targeted therapy for ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... designed for flexibility and routine operation. With ... lens, true hyperbolic quadrupole and high-speed simultaneous ... range of sample types and applications. New ... standard Agilents unique ShieldTorch System, which enables ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
Biology Products: